Biotech Values

[zipjet]

Copaxone vs Tysabri in the US Market

Or you could say sequential growth in the latest Q was:

Copaxone 1.9%
Tysabri 7.7%

Unless there was a price increase for Tysabri or some other distortion, Tysabri performed relatively better.

IF the neuro's treating MS get more comfortable with the PML risk, Tysabri could gain a lot on it's superior patient outcomes.

Thanks for the data table.

ij